Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Incyte ( (INCY) ) just unveiled an announcement.
On February 27, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter to Incyte for its supplemental Biologics License Application seeking to expand Zynyz’s use to adult patients with metastatic non-small cell lung cancer in combination with platinum-based chemotherapy. The filing was backed by positive Phase 3 POD1UM-304 data reported in December 2024.
The FDA cited regulatory compliance issues at Catalent Indiana, the third-party fill-finish facility owned by Novo Nordisk and referenced in the application, as the sole obstacle to approval, without raising concerns about Zynyz’s efficacy, safety or its drug substance manufacturer. Incyte is collaborating with the FDA and Catalent Indiana to resolve the manufacturing site findings and enable a potential resubmission, delaying expansion of Zynyz’s NSCLC label but preserving the therapy’s clinical profile in this indication.
The most recent analyst rating on (INCY) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on Incyte stock, see the INCY Stock Forecast page.
Spark’s Take on INCY Stock
According to Spark, TipRanks’ AI Analyst, INCY is a Outperform.
Score is driven primarily by strong financial strength (low leverage, high margins, and a major 2025 profitability/cash rebound) and supportive technical momentum (price above major moving averages with positive MACD). The rating is moderated by profit/cash-flow volatility over time, reasonable-but-not-bargain valuation (P/E ~18.3 with no dividend), and earnings-call execution risks (PN setback, higher R&D, and the need to broaden growth beyond Jakafi).
To see Spark’s full report on INCY stock, click here.
More about Incyte
Incyte Corporation is a biopharmaceutical company focused on developing and commercializing innovative oncology therapies, including immunotherapies such as Zynyz (retifanlimab-dlwr). The company targets serious unmet medical needs in cancer, pursuing indications like metastatic non-small cell lung cancer in combination with standard treatments.
Average Trading Volume: 1,997,220
Technical Sentiment Signal: Buy
Current Market Cap: $19.37B
For detailed information about INCY stock, go to TipRanks’ Stock Analysis page.
